{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:18:15Z","timestamp":1780960695772,"version":"3.54.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Acute bacterial skin and skin structure infections (ABSSSI) are serious infections of the skin and subcutaneous tissue that include major cutaneous abscesses, cellulitis\/erysipelas, and wound infections. ABSSSI caused by Gram-positive pathogens are common in children, who tend to experience high rates of morbidity and hospitalization due to ABSSSI, including those caused by antibacterial-resistant pathogens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This phase 3 study (NCT03176134) investigated the safety of tedizolid phosphate and its ability to treat ABSSSI in pediatric participants 28 days to &lt;12 years of age. A total of 100 participants were randomized 3:1 to intravenous and\/or oral tedizolid phosphate for 6\u201310 days or intravenous and\/or oral comparator for 10\u201314 days; participants were stratified and enrolled by age cohort. The primary objective was to evaluate the safety of tedizolid phosphate versus comparators using descriptive statistics. The secondary objective was to evaluate clinical response at the test-of-cure (TOC) visit in the intent-to-treat and clinically evaluable populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Tedizolid phosphate was well tolerated, and adverse events were comparable between the tedizolid phosphate and comparator groups. Clinical success rates at the TOC visit in the intent-to-treat and clinically evaluable populations were high (&gt;90%) and comparable between groups. All participants in the tedizolid phosphate treatment group who had skin culture results at baseline experienced favorable microbiological response at the TOC visit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The results of this study provide evidence to support the use of tedizolid phosphate to treat ABSSSI caused by Gram-positive pathogens in pediatric patients from 28 days to &lt;12 years of age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004807","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:00:09Z","timestamp":1744732809000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients &lt;12 Years of Age With Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1097","volume":"44","author":[{"given":"Rosie","family":"Mngqibisa","sequence":"first","affiliation":[{"name":"Enhancing Care Foundation, King Edward Hospital, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Fofanov","sequence":"additional","affiliation":[{"name":"Ivano-Frankivsk Regional Children Clinical Hospital, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos F.","family":"Grazioso","sequence":"additional","affiliation":[{"name":"Center for Pediatric Research, Guatemala City, Guatemala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Melgar Toledo","sequence":"additional","affiliation":[{"name":"Centro de Estudios Cl\u00ednicos Salud Avanzada, Guatemala City, Guatemala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Boddicker","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Broyde","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Koseoglu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Romero","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Stevens","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sears","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"R1-20250805","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/cid\/civ528","article-title":"Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.","volume":"61","author":"Cardona","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"106637","DOI":"10.1016\/j.ijantimicag.2022.106637","article-title":"Skin infections in Europe: a retrospective study of incidence, patient characteristics and practice patterns.","volume":"60","author":"Grossi","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R3-20250805","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.","volume":"4","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-14-296","article-title":"Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009.","volume":"14","author":"Suaya","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/INF.0000000000000304","article-title":"Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection.","volume":"33","author":"Moore","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20250805","article-title":"Antimicrobial resistance surveillance in Europe 2023 - 2021 data."},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-015-0060-3","article-title":"Tedizolid phosphate: a next-generation oxazolidinone.","volume":"4","author":"Rybak","year":"2015","journal-title":"Infect Dis Ther"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"e0089521","DOI":"10.1128\/AAC.00895-21","article-title":"Population pharmacokinetics, exposure-response, and probability of target attainment analyses for tedizolid in adolescent patients with acute bacterial skin and skin structure infections.","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20250805","article-title":"Sivextro\u00ae summary of product characteristics."},{"key":"R10-20250805","article-title":"Assessment report: Sivextro."},{"key":"R11-20250805","article-title":"Sivextro\u00ae prescribing information."},{"key":"R12-20250805","article-title":"Highlights of prescribing information: Sivextro."},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"e02252","DOI":"10.1128\/AAC.02252-18","article-title":"Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection.","volume":"63","author":"Lv","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections.","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20250805","article-title":"A study of safety and efficacy of MK-1986 (tedizolid phosphate) and comparator in participants from birth to less than 12 years of age with acute bacterial skin and skin structure infections (MK-1986-018)."},{"key":"R16-20250805","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/phar.1458","article-title":"Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R17-20250805","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1214\/14-EJS909","article-title":"The cost of using exact confidence intervals for a binomial proportion.","volume":"8","author":"Thulin","year":"2014","journal-title":"Electron J Stat"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"R19-20250805","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14787210.2023.2182769","article-title":"Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.","volume":"21","author":"Volpicelli","year":"2023","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:05:56Z","timestamp":1754427956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004807","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}